Gilead Sciences, Inc. (NASDAQ:GILD) Declares $0.79 Quarterly Dividend

Key Points

• Gilead Sciences, Inc. declared a quarterly dividend of $0.79 per share, with a payment date set for September 29th for shareholders on record as of September 15th, yielding 2.6% annually.
• The company reported $7.08 billion in revenue and $2.01 EPS for the latest quarter, exceeding analyst expectations and reflecting a 1.4% increase year-over-year.
• Gilead Sciences has a healthy dividend payout ratio of 37.1%, indicating strong earnings support for its $3.16 annual dividend and expected future earnings growth.

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) declared a quarterly dividend on Friday, August 8th, Wall Street Journal reports. Stockholders of record on Monday, September 15th will be paid a dividend of 0.79 per share by the biopharmaceutical company on Monday, September 29th. This represents a c) dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Monday, September 15th.

Gilead Sciences has a payout ratio of 37.1% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Gilead Sciences to earn $8.11 per share next year, which means the company should continue to be able to cover its $3.16 annual dividend with an expected future payout ratio of 39.0%.

Gilead Sciences Price Performance

Shares of GILD traded up $0.25 during trading hours on Tuesday, hitting $120.72. The stock had a trading volume of 986,391 shares, compared to its average volume of 8,372,609. The company's fifty day moving average is $111.16 and its two-hundred day moving average is $107.83. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences has a 52 week low of $72.67 and a 52 week high of $121.82. The stock has a market capitalization of $149.79 billion, a price-to-earnings ratio of 24.03, a P/E/G ratio of 0.75 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the prior year, the firm earned $2.01 EPS. The firm's quarterly revenue was up 1.4% compared to the same quarter last year. On average, analysts anticipate that Gilead Sciences will post 7.95 EPS for the current year.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.